Laribi K, et al. - Researchers determined how overall survival (OS) in myelodysplastic syndromes (MDS) patients with intermediate 2 or high-risk IPSS score was influenced by azacitidine (AZA) relative dose intensity (RDI) <80% in this retrospective analysis of 93 MDS cases. The full dose was administered in 51.6% of patients while 48.4% had dose reduction or delayed with a RDI <80%. For the entire population, 58% and 47% were the estimated overall and progression-free survivals (OS, PFS) probabilities at 1 year; they were 35% and 31% for two years, respectively. Compared to patients who had dose reduction after achieving response, a significantly lower OS and PFS were observed among those who had treatment dose reduced prior to achieving the objective response. In multivariate analysis, OS and PFS were significantly influenced by acute myeloid leukemia with 21%-30% blasts in BM and poor and very poor karyotype.